The article reviews the nutraceutical properties of C-phycocyanin (C-PC), a water-soluble phycobiliprotein derived from *Arthrospira platensis* (Spirulina). C-PC, the most abundant protein in Spirulina, is known for its fluorescent properties and is widely used in food coloring. However, it also exhibits numerous health-promoting effects due to its antioxidant, anti-inflammatory, anticancer, hypolipidemic, anti-diabetic, hepatoprotective, neuroprotective, and other pharmacological activities. These effects are attributed to C-PC's ability to scavenge free radicals, inhibit inflammatory pathways, and modulate gene expression. The review highlights the potential of C-PC and its chromophore, phycocyanobilin B (PCB-B), in treating various diseases, including neurodegenerative disorders, diabetes, obesity, hypertension, and renal failure. Additionally, C-PC and PCB-B show promise in addressing aging, toxic exposure, cataracts, hearing loss, and infertility. The article emphasizes the need for more clinical trials to fully understand the pharmacokinetic profile and optimal dosage of these compounds in humans.The article reviews the nutraceutical properties of C-phycocyanin (C-PC), a water-soluble phycobiliprotein derived from *Arthrospira platensis* (Spirulina). C-PC, the most abundant protein in Spirulina, is known for its fluorescent properties and is widely used in food coloring. However, it also exhibits numerous health-promoting effects due to its antioxidant, anti-inflammatory, anticancer, hypolipidemic, anti-diabetic, hepatoprotective, neuroprotective, and other pharmacological activities. These effects are attributed to C-PC's ability to scavenge free radicals, inhibit inflammatory pathways, and modulate gene expression. The review highlights the potential of C-PC and its chromophore, phycocyanobilin B (PCB-B), in treating various diseases, including neurodegenerative disorders, diabetes, obesity, hypertension, and renal failure. Additionally, C-PC and PCB-B show promise in addressing aging, toxic exposure, cataracts, hearing loss, and infertility. The article emphasizes the need for more clinical trials to fully understand the pharmacokinetic profile and optimal dosage of these compounds in humans.